UCB Raises 2026 Guidance on Strong US Bimzelx Sales
UCB said stronger-than-expected US sales of Bimzelx drove its upgraded 2026 financial outlook. The available report truncates before giving the updated growth figures.
Belgian biopharmaceutical group UCB EURONEXT:UCB upgraded its 2026 financial guidance on Thursday, driven by the stronger performance of its blockbuster drug Bimzelx in the US.The company expects adjusted earnings before interest, taxes, depreciation and amortization growth in the low- to mid-forti…